Antibiotic Incentives Helped Spero Get Where It Is Today

The firm is developing a novel class of antibacterials that could enable shelved agents for Gram-positive infections to reach and kill Gram-negative bacteria.

antibiotics, pills and injection

More from Clinical Trials

More from R&D